RIO2026

XXIII WORLD CONGRESS ON GESTATIONAL TROPHOBLASTIC DISEASE



NOVEMBER 10-13, 2026

RIO DE JANEIRO • BRAZIL

FINAL PROGRAMME

ORGANIZED BY

International Society for the Study of Trophoblastic Diseases

Associação Brasileira de Doença Trofoblástica Gestacional

SUPPORTED BY

CNPq

FAPERJ

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

ISSTD2026CONGRESS.COM

ISSTD 2026

Contents

SCIENTIFIC PROGRAMME

General Information

10 November 2026
Tuesday / Education Day

11 November 2026
Wednesday

12 November 2026
Thursday

13 November 2026
Friday

RIO DE JANEIRO • BRAZIL

GENERAL INFORMATION

OPENING OF THE MEETING (EDUCATION DAY)

08:00 AM – 08:30 AM

Antonio Rodrigues Braga Neto (RJ, Brazil)
President of the Meeting

Golfier François Prof., MD, PhD, HDR
(Métropole de Lyon, France)
ISSTD President

OPENING REMARKS

08:00 AM – 08:30 AM

Golfier François Prof., MD, PhD, HDR
(Métropole de Lyon, France)
ISSTD President

Antonio Rodrigues Braga Neto (RJ, Brazil)
President of the Meeting

CERTIFICATES

All certificates will be issued online and will be available on the conference's official website within seven (7) business days after the event.

REGISTRATION DESK

- Nov. 10: 7 AM to 6:45 PM
- Nov. 11: 7:20 to 5:30 PM
- Nov. 12: 7:00 AM to 13 PM
- Nov. 13: 7:00 AM to 13 PM

ISSTD 2026

SCIENTIFIC PROGRAMME

10 NOVEMBER 2026

TUESDAY / EDUCATION DAY



RIO DE JANEIRO • BRAZIL

08:00 – 08:30 • Opening of the Meeting

Antonio Rodrigues Braga Neto (RJ, Brazil)
President of the Meeting

Golfier François (Métropole de Lyon, France)
ISSTD President

08:30 – 10:00 • Education Session 1

08:30 – 08:40 • hCG assays/low level/Hook
Lea Ghataore (Surrey, UK)
Speaker

08:40 – 08:55 • Genetics
Geoffrey Maher (Hammersmith and Fulham, UK)
Speaker

08:55 – 09:10 • Pathology
Lawrence Hsu Lin (Massachusetts, USA)
Speaker

09:10 – 09:25 • CHM/PHM
Gabriela Paiva (RJ, Brazil)
Speaker

09:25 – 09:40 • FIGO SCORING / New staging
Neil Horowitz (USA)
Speaker

09:40 – 10:00 • Q&A

10:00 – 10:30 • Coffee Break

10:30 – 12:00 • Education Session 2

10:30 – 10:50 • LR/HR GTN
Prof Pierre-Adrien Bolze (Lyon, France)
Speaker

10:50 – 11:10 • UHR/Relapse
Prof Michael J Seckl (UK)
Speaker

11:10 – 11:30 • PSTT / ETT / aPSN
Ulrika Joneborg (Stockholms län, Sweden)
Speaker

11:30 – 12:00 • Q&A

12:00 – 13:00 • Lunch Break

13:00 – 14:30 • Education Session 3

13:00 – 13:20 • Management of Bleeding – with descriptive case
Kevin Elias (Ohio, USA)
Speaker

13:20 – 13:40 • Immunotherapy Toxicity and Management + case
Matthew Winter MD (England, UK)
Speaker

13:40 – 14:20 • MDT tumor board
Jiang, Fang (Beijing Shi, People's Republic of China)
Speaker

14:30 – 15:00 • Coffee Break

15:00 – 16:30 • Education Session 4

15:00 – 15:25 • 10 steps to establishing a GTD specialist centre
John Coulter (Cork, Ireland)
Speaker

15:25 – 15:30 • Five Years of National Gestational Trophoblastic Disease Care in Sweden: Quality Indicators and Outcomes from the Swedish National GTD Center
Ulrika Joneborg (Stockholms län, Sweden)
Presenter

15:30 – 15:40 • Beyond Clinical Care: The Specialist Nurse at the Heart of a GTD Reference Centre
Kam Singh, Nurse Consultant (Sheffield, UK)
Speaker

15:40 – 15:45 • The Role of the Clinical Nurse Specialist in a Centralized Gestational Trophoblastic Disease Center
Linda Fridell (Stockholms län, Sweden)
Presenter

15:45 – 15:50 • Gestational trophoblastic neoplasia in Argentina: a national multicenter analysis by risk group, treatment response, and outcome (2000-2026)
Jesica Storino (Buenos Aires, Argentina)
Presenter

15:50 – 15:55 • Exploratory and Expert-Based Insights into Gestational Trophoblastic Disease Registry Design: A Socio-Ecological Perspective
Dr. Maria Stephanie Fay S. Cagayan (National Capital Region, Philippines)
Presenter

15:55 – 16:00 • Gestational trophoblastic neoplasia in the Western Brazilian Amazon: patient characteristics and impact of referral center restructuring
Bruno Paolino (AM, Brazil)
Presenter

16:00 – 16:30 • Evaluation of the Characteristics of Gestational Trophoblastic Disease Reference Centers in Brazil
Daniela Yela (SP, Brazil)
Presenter

16:05 – 16:10 • Gestational Trophoblastic Neoplasia Following Hydatidiform Mole and Non-Molar Pregnancy: Clinical and Prognostic Features from a 40-Year Cohort Study at a Reference Center in Southern Brazil
Elza Hartmann Uberti (RS, Brazil)
Presenter

16:10 – 16:15 • Care indicators and follow-up records for patients with gestational trophoblastic disease at a referral centre in northern Santa Catarina
José Eduardo Gauza (SC, Brazil)
Presenter

16:15 – 16:20 • Growth of the Spanish Gestational Trophoblastic Disease Registry (GEICO 81-T): Updated Clinical Characteristics and Outcomes of the First 60 Patients
Gloria Marquina (Madrid, Spain)
Presenter

16:20 – 16:30 • Q&A

16:30 • Close of Session

16:45 – 18:45 • ISSTD Executive Board Meeting

ISSTD 2026

Welcome Cocktail

Tuesday, November 10

Orla 21 Rooftop (5th floor)

19:00 – 21:00



ISSTD 2026

SCIENTIFIC PROGRAMME

11 NOVEMBER 2026

WEDNESDAY



RIO DE JANEIRO • BRAZIL

08:00 – 08:30 • Opening Remarks

Golfier François (Métropole de Lyon, France)
ISSTD President

Antonio Rodrigues Braga Neto (RJ, Brazil)
President of the Meeting

08:30 – 10:00 • Session 1
Clinical Trials

Andy Garrett (Queensland, Australia)
Chair

Golfier François (Métropole de Lyon, France)
Chair

08:30 – 08:40 • Impact of second curettage for women with low-risk non-metastatic gestational trophoblastic neoplasia RECure trial
Dr. Marcio Barcellos (RJ, Brazil)
Speaker

08:40 – 08:45 • Q&A

08:45 – 08:55 • Hysterectomy versus uterine curettage as first-line management of hydatidiform mole in women aged 40 years and older: a target trial emulation from the MATURA-40 cohort
Lua Eiriksson (Ontario, Canada)
Presenter

08:55 – 09:00 • Q&A

09:00 – 09:10 • RESOLVE: A randomised phase II feasibility study of single dose pembrolizumab prior to second evacuation for low risk postmolar GTN
Dr. Ehsan Ghorani (England, UK)
Presenter

09:10 – 09:15 • Q&A

09:15 – 09:25 • Survivorship Outcomes After Methotrexate-Folinic Acid Versus Actinomycin D for Low-Risk Gestational Trophoblastic Neoplasia: Extended Follow-up of a Randomized Trial
Jiang, Fang (Beijing Shi, People's Republic of China)
Presenter

09:25 – 09:30 • Q&A

09:30 – 09:40 • Prophylactic Intrathecal Methotrexate in Stage III Gestational Trophoblastic Neoplasia: Results from an Extended International Retrospective Cohort (PitMex)
Prof Pierre-Adrien Bolze (Lyon, France)
Presenter

09:40 – 09:45 • Q&A

09:45 – 09:55 • Camrelizumab plus apatinib and chemotherapy in high-risk, chemotherapy-resistant or recurrent gestational trophoblastic neoplasia (CAP 07): A single-arm, phase II trial
Jiang, Fang (Beijing Shi, People's Republic of China)
Presenter

09:55 – 10:00 • Q&A

10:00 – 10:30 • Session 2
Patient experience 1

Kam Singh, Nurse Consultant (Sheffield, UK)
Chair

Gabriela Paiva (RJ, Brazil)
Chair

10:00 – 10:05 • "I'm just worn out by the whole thing": A mixed methods study of contraceptive use among patients with gestational trophoblastic neoplasia
Brittany Davidson (North Carolina, USA)
Presenter

10:05 – 10:10 • Experiences of pregnancy loss in Gestational Trophoblastic Neoplasia
Kam Singh, Nurse Consultant (Sheffield, UK)
Presenter

10:10 – 10:15 • Patient Experiences During follow-up after a Diagnosis of Complete Hydratidform mole
Emmy Wakaeng (Stockholms län, Sweden)
Presenter

10:15 – 10:20 • Frequency and Factors Associated with Sexual Dysfunction and Reproductive Concerns Among Patients Diagnosed with Gestational Trophoblastic Disease in a Referral Center in the Western Brazilian Amazon
Michelle Paolino (AM, Brazil)
Presenter

10:20 – 10:30 • Q&A

10:30 – 11:00 • Coffee and Posters

11:00 – 12:35 • Session 3
Disease markers and APSN/PSTT/ETT

Kevin Elias (Ohio, USA)
Chair

11:00 – 11:10 • Analytical and clinical evaluation of the Roche Elecsys hCG+ Assay to replace the Siemens Immulite 2000 Xpi hCG assay for monitoring Gestational Trophoblastic Disease
Lea Ghataore (Surrey, UK)
Presenter

PROGRAM • NOV. 11, 2026 | CORCOVADO ROOM

11:10 – 11:20 • False elevation of hCG during surveillance caused by biotin supplementation: Case report and literature review
Kevin Elias (Ohio, USA)
Presenter

11:20 – 11:25 • Cost-of-Illness of Gestational Trophoblastic Disease in the Philippines: Policy-Relevant Estimates from Model Patient Scenarios
Dr. Maria Stephanie Fay S. Cagayan (National Capital Region, Philippines)
Presenter

11:25 – 11:30 • Q&A

11:30 – 11:35 • Proteomics and Hydatidiform Moles
Cathrine Linnea Hegtmann (Region Nordjylland, Denmark)
Presenter

11:35 – 11:40 • cfDNA as biomarker for GTN
Cathrine Sylvester (Region Nordjylland, Denmark)
Presenter

11:40 – 11:50 • Transcriptomic analysis of PSTT and ETT identifies novel diagnostic and prognostic biomarkers
Geoffrey Maher (Hammersmith and Fulham, UK)
Presenter

11:50 – 12:00 • DNA methylation landscape of placental site and epithelioid trophoblastic tumours
Melissa Cheung (London, City of, UK)
Presenter

12:00 – 12:05 • Q&A

12:05 – 12:15 • Sentinel lymph node biopsy in placental site and epithelioid trophoblastic tumors: feasibility and potential impact on treatment strategy
Prof Pierre-Adrien Bolze (Lyon, France)
Presenter

12:15 – 12:25 • Atypical Placental Site Nodule: Assessing Malignant Potential and Clinical Significance
Naveed Sarwar MD PhD
Presenter

12:25 – 12:30 • Atypical placental site nodule: Audit of cases registered with the Queensland Trophoblast Centre
Andy Garrett (Queensland, Australia)
Presenter

12:30 – 12:35 • Q&A

12:35 – 14:00 • Lunch and poster viewing and research meeting

14:00 – 15:30 • Session 4
GTN Potpourri or luckydip or smorgasbord

Dr. Ehsan Ghorani (England, UK)
Chair

14:00 – 14:10 • One-year shortened follow-up data for complete hydatidiform mole (CHM) patients using urinary hCG followed by confirmatory serum hCG in a UK GTD centre:does the use of urinary hCG influence follow-up?
Kam Singh, Nurse Consultant (Sheffield, UK)
Presenter

14:10 – 14:15 • Risk of Postmolar Gestational Trophoblastic Neoplasia After hCG Normalization: A Nationwide Population-Based Study With Centralized Reference Pathology
Alice Joneborg (Skåne län, Sweden)
Presenter

14:15 – 14:20 • Intraplacental Choriocarcinoma: neonatal and maternal evolution in a series of 21 cases
Dr Jerome Massardier (Auvergne-Rhône-Alpes, France)
Presenter

14:20 – 14:30 • Who Can Avoid Chemotherapy? Predictors of Successful First-Line Hysterectomy in FIGO High-Risk GTN
Golfier François (Métropole de Lyon, France)
Presenter

14:30 – 14:35 • Patterns of care of gestational trophoblastic disease in Ontario: a population-based study
Geneviève Bouchard-Fortier (Ontario, Canada)
Presenter

14:35 – 14:40 • National Centralization of Gestational Trophoblastic Disease Diagnostics: A 2021–2025 Swedish Reference Laboratory Experience
Sandra Wessman (Region Stockholm, Sweden)
Presenter

14:40 – 14:45 • Gestational Trophoblastic neoplasia primary prevention with short-term high-dose vitamin A in postmolar patients with low-level plateaued human chorionic gonadotropin: a two cohorts study
Elza Hartmann Uberti (RS, Brazil)
Presenter

14:45 – 14:55 • Q&A

14:55 – 15:30 • A Clinical case from Rwanda MDT last week

15:30 – 16:30 • Session 5: Poster Session with judging/Coffee break

Prof Pierre-Adrien Bolze (Lyon, France)
Chair

Izildinha Maesta (SP, Brazil)
Chair

16:30 – 17:30 • Society Meetings

ISSTD 2026

SCIENTIFIC PROGRAMME

12 NOVEMBER 2026

THURSDAY



RIO DE JANEIRO • BRAZIL

08:00 – 08:30 • Announcements

08:30 – 09:20 • Session 6
Pregnancy/Fertility Related Issues

Reda Hemida (**Mansoura University,** Egypt)
Chair

Dr. Maria Stephanie Fay S. Cagayan (National Capital Region, Philippines)
Chair

08:30 – 08:40 • Pregnancy in the first versus second year of follow-up after chemotherapy for gestational trophoblastic neoplasia: a review of the Charing Cross Gestational Trophoblastic Disease Service
Lua Eiriksson (Ontario, Canada)
Presenter

08:40 – 08:50 • Evaluation of fertility outcomes following chemotherapy (CT) treatment in a specialist GTN centre 1995 – 2020
Matthew Winter MD (England, UK)
Presenter

08:50 – 09:00 • Fertility and pregnancy outcomes after treatment with avelumab (anti-PD-L1) for gestational trophoblastic tumors: the FERTILAVE study
Adrien Msika (Rhône, France)
Presenter

09:00 – 09:10 • Tracking the Cesarean Delivery–Postmolar Gestational Trophoblastic Neoplasia Link
Gabriela Paiva (RJ, Brazil)
Presenter

09:10 – 09:15 • Clinical and paraclinical features of patients with diagnosis of benign trophoblastic tissue sequestration to avoid misdiagnosis of gestational trophoblastic neoplasia
Prof. Rafael Cortés Charry (Distrito Capital, Venezuela)
Presenter

09:15 – 09:20 • Q&A

09:20 – 10:25 • Session 7
Minimum data sets and FIGO scoring/AI

Christianne Lok (Netherlands)
Chair

Raphael Alevato (RJ, Brazil)
Chair

09:20 – 09:27 • The CODING Study: An International Service Evaluation of Data Recording Practices in Gestational Trophoblastic Disease
Aoife Corcoran (Limerick, Ireland)
Presenter

09:27 – 09:35 • A Systematic Review of Outcomes Reported in Gestational Trophoblastic Disease to Inform the Development of a Core Outcome Set
Aoife Corcoran (Limerick, Ireland)
Presenter

09:35 – 09:40 • Q&A

09:40 – 09:50 • Variability in FIGO Risk Scoring for Gestational Trophoblastic Neoplasia: Clinicians Versus Large Language Models
Christianne Lok (Netherlands)
Presenter

09:50 – 09:55 • Development of an Interactive International E-Learning Program for Gestational Trophoblastic Disease Based on Global Guidelines and Expert Case-Based Learning
Christianne Lok (Netherlands)
Presenter

09:55 – 10:05 • A free, offline decision-support tool for gestational trophoblastic disease surveillance, staging and referral where specialist access is limited
Dra. Diana Ivy Anca Vega (Distrito Capital, Venezuela)
Presenter

10:05 – 10:10 • Knowledge, Attitudes, and Practices of Medical Trainees and Specialists Regarding Gestational Trophoblastic Disease
Beatriz Pinheiro (SP, Brazil)
Presenter

10:10 – 10:15 • Sociodemographic Factors and Delays in Care for Gestational Trophoblastic Neoplasia
Tara Markert (North Carolina, USA)
Presenter

10:15 – 10:20 • Association of Facebook Messenger Group on Adherence to Post-treatment β-hCG Monitoring among Patients with Gestational Trophoblastic Disease in a Government Tertiary Hospital
Maria Febi Billones De Ramos (Metro Manila, Philippines)
Presenter

10:20 – 10:25 • Q&A

10:25 – 10:50 • Coffee Break

10:50 – 12:02 • Session 8
Low risk GTN chemotherapy, resistance and relapse

Ulrika Joneborg
Chair

Fernanda Freitas (RJ, Brazil)
Chair

10:50 – 11:00 • Low risk gestational trophoblastic neoplasia with primary resistance to methotrexate should be treated with multi-agent chemotherapy rather than single agent Actinomycin D
Branco-Silva (SP, Brazil)
Presenter

11:00 – 11:10 • Can the hCG threshold for actinomycin D be increased above 10,000 IU/L in methotrexate-resistant low-risk gestational trophoblastic neoplasia?
Firas Charfare (Barnet, UK)
Presenter

11:10 – 11:20 • Dactinomycin salvage monotherapy for Methotrexate-resistant Low-risk Gestational Trophoblastic Neoplasia: A Single-arm Meta-Analysis of Pulsed and Five-Day regimens
Julia Molisani (MT, Brazil)
Presenter

11:20 – 11:25 • Single-Dose Prophylactic Actinomycin D Administered During Uterine Evacuation Reduces the Incidence and Morbidity of Post-Molar Gestational Trophoblastic Neoplasia: A 28-Year Cohort Study
Elza Hartmann Uberti (RS, Brazil)
Presenter

11:25 – 11:30 • Outcomes of first-line pulse actinomycin-D for low-risk gestational trophoblastic neoplasia: a multi-institutional Canadian study
Brenna Swift (Ontario, Canada)
Presenter

11:30 – 11:35 • An international multi-centre cohort study comparing actinomycin-D vs multi-agent chemotherapy for relapsed low risk gestational trophoblastic neoplasia previously treated with methotrexate
Firas Charfare (Barnet, UK)
Presenter

11:35 – 11:40 • Q&A

12:02 – 13:00 • Lunch Break

ISSTD 2026

SCIENTIFIC PROGRAMME

13 NOVEMBER 2026

FRIDAY



RIO DE JANEIRO • BRAZIL

08:00 – 08:30 • DEBATE

What to do at first line resistance? Are hCG cut-offs really necessary?

Pro: **Lua Eiriksson** (Ontario, Canada)
Con: **Nienke van Tromel** (Utrecht, Netherlands)

08:25 – 08:29 • Q&A

08:29 – 08:30 • Voting

08:30 – 10:00 • Session 9
Immunotherapy

Daniela Yela (SP, Brazil)
Chair

08:30 – 08:40 • Seven years follow-up of adjuvant pembrolizumab for poor prognosis gestational trophoblastic neoplasia (GTN)
Dr. Ehsan Ghorani (England, UK)
Presenter

08:40 – 08:50 • Carboplatin, paclitaxel, and pembrolizumab: a novel salvage treatment for chemotherapy-resistant or recurrent gestational trophoblastic neoplasia
Lua Eiriksson (Ontario, Canada)
Presenter

08:50 – 09:00 • Compassionate use of pembrolizumab for stage I placental site trophoblastic tumor in patients of reproductive age declining hysterectomy
Adrien Msika (Rhône, France)
Presenter

09:00 – 09:10 • A decade of pembrolizumab in gestational trophoblastic neoplasia: an update of the international database
Firas Charfare (Barnet, UK)
Presenter

09:10 – 09:15 • Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors
Dr. Marcio Barcellos (RJ, Brazil)
Presenter

09:15 – 09:20 • Q&A

09:20 – 09:30 • Avelumab plus methotrexate versus methotrexate alone as first-line treatment in low-risk gestational trophoblastic neoplasia: an external control comparison
Prof Pierre-Adrien Bolze (Lyon, France)
Presenter

09:30 – 09:40 • Pregnancy outcomes following pembrolizumab treatment for gestational trophoblastic neoplasia
Firas Charfare (Barnet, UK)
Presenter

09:40 – 09:50 • Avelumab + methotrexate as first-line treatment for low-risk gestational trophoblastic tumors: updated outcomes of TROPHAMET trial enriched with a real-life compassionate-access cohort
You (Rhône, France)
Presenter

09:50 – 09:55 • Persistent low-level real human chorionic gonadotropin after gestational trophoblastic disease: natural history and predictors of subsequent gestational trophoblastic neoplasia
Raphael Alevato (RJ, Brazil)
Presenter

09:55 – 10:00 • Q&A

10:00 – 10:30 • Immune Responses to Trophoblast

Victoria Male, Imperial College London (UK)
Speaker

10:30 – 11:30 • Coffee and Posters

11:30 – 12:25 • Session 10
Patient Experience 2

Prof. Rafael Cortés Charry (Distrito Capital, Venezuela)
Chair

Gabriel Costa Osanan (MG, Brazil)
Chair

11:30 – 11:40 • Trends in First-Line Chemotherapy for the Low-Risk Gestational Trophoblastic Neoplasia in Ontario
Geneviève Bouchard-Fortier (Ontario, Canada)
Presenter

11:40 – 11:50 • Reproductive outcomes and age at menopause following chemotherapy for gestational trophoblastic neoplasia
Leigh Jenkins (Dundee City, UK)
Presenter

11:50 – 11:55 • Lost in Translation: Exploring the Experiences of Limited English Proficient patients diagnosed with Gestational Trophoblastic Disease/Gestational Trophoblastic Neoplasia
Kam Singh, Nurse Consultant (Sheffield, UK)
Presenter

11:55 – 12:00 • Outcome of Molar Pregnancies in women 20 Years or younger at Mansoura University Hospital
Reda Hemida (**Mansoura University**, Egypt)
Presenter

12:00 – 12:05 • Gestational trophoblastic disease in indigenous women from Western Amazonas: a case series highlighting diagnostic and treatment challenges
Michelle Paolino (AM, Brazil)
Presenter

12:05 – 12:10 • Unspecified Hydatidiform Mole as a Time-Varying Classification Bias in Predicting Gestational Trophoblastic Neoplasia: A 31-year Brazilian Cohort
Felipe Grillo (PR, Brazil)
Presenter

12:10 – 12:15 • Translating Evidence into Practice: A Framework for Safe Home-Based Administration of Methotrexate/Folinic Acid in Low-Risk GTN
Valdete (SP, Brazil)
Presenter

12:15 – 12:25 • Q&A

12:25 – 13:00 • ISSTD General assembly of members, AWARDS and CLOSING

13:00 – 14:00
Lunch and Farewell

BECOME A MEMBER

ISSTD International Society for the Study of Trophoblastic Diseases

Join a global community of professionals. Find all the information about ISSTD and register or renew your membership!

isstd.org